Regional Cancer Care Associates, LLC

East Brunswick, New Jersey 08816

1 studies enrolling now · 6 studies all time

What they study most

Adenocarcinoma, Carcinoma, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung, Lung Neoplasm, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Triple Negative Breast Cancer

Studies at this site

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Running, not enrolling
• Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma — APPROVED_FOR_MARKETING
• TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy — Stopped early
• TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy — Stopped early
• Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly — Completed